bFGF Peptide Synergistic Vitiligo Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vitiligo, such as PUV-A therapy and steroids, have limited effectiveness, with only 50% repigmentation success and side effects, and fail to address fast-spreading cases and long treatment durations.
Innovation Solution
A combinatorial synergistic therapy using local application of bFGF peptides in combination with PUV-A therapy, steroid therapy, or surgical procedures to enhance melanocyte proliferation and migration, thereby accelerating repigmentation and arresting disease spread.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PUV-A therapy is used for vitiligo treatment, then repigmentation occurs in about 50% of cases, but the treatment duration is long and many patches remain unresponsive
Solution Approach 1:
The patent combines bFGF peptide therapy with PUV-A therapy to create a synergistic treatment approach. The bFGF peptide (0.02-5% w/w) is applied topically to stimulate melanocyte proliferation and migration, while PUV-A therapy provides photostimulation. This combination merges two mechanisms of action to achieve higher repigmentation success rates (over 80% in clinical trials) and reduces treatment duration compared to PUV-A alone.
2Reliability
If traditional therapies like PUV-A or steroids are used, then some repigmentation is achieved, but side effects occur and fast-spreading cases are not effectively managed
Solution Approach 1:
The patent introduces bFGF peptide at specific concentrations (0.02-5% w/w) to change the therapeutic parameter profile. This peptide stimulates melanocyte proliferation and migration through biological signaling pathways without the immunosuppressive side effects of steroids or the photosensitivity risks of PUV-A monotherapy. The controlled delivery system ensures optimal peptide concentration at the skin level, achieving effective repigmentation while minimizing harmful effects.
3Reliability
If long duration PUV-A therapy is administered, then partial repigmentation may occur, but many patches remain unresponsive even after extended treatment
Solution Approach 1:
The bFGF peptide is applied in advance of or concurrently with PUV-A therapy to pre-stimulate melanocyte proliferation and migration. This preliminary biological priming creates a more responsive cellular environment before photostimulation occurs, enhancing the overall treatment efficacy and reducing the time required to achieve repigmentation in previously unresponsive patches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The therapy achieves over 80% success rate in stable vitiligo cases, significantly improves repigmentation speed, and effectively manages fast-spreading vitiligo, reducing treatment duration and side effects.
Implementation Method 1
Basic fibroblast growth factor (bFGF) also known as FGF2 is a potent mitogen for a variety of cell types including melanocytes
Implementation Method 2
photo chemotherapy with topical/oral psoralens followed by exposure to ultra violet A radiation (PUV-A)
Data Source
AI summary
Synergistic therapies for the treatment of vitiligo are provided, in which basic fibroblast growth factor peptide(s) lotion was developed as a new mode of therapy for the treatment of vitiligo. It went through various phases of successful clinical trials in India and is marketed by the drug controller general (India). It is effective in 80% of stable and segmental vitiligo. Data are provided which demonstrate that combinatorial treatment of vitiligo by local application of bFGF peptide(s) lotions in association with psoralens and UV-A, or steroids or surgical procedures, produce a synergistic response in which the rate of repigmentation increases synergistically and more efficacious results are obtained than with any one of them alone. Any combinatorial therapy comprising the local application of bFGF peptide(s) lotion on the vitiligo patch in combination with any other therapies for the treatment of vitiligo also may act synergistically.